PLx Pharma Inc. [NASDAQ: PLXP] stock went on an upward path that rose over 17.77% on Monday, amounting to a one-week price increase of more than 20.19%. The company report on March 1, 2021 that PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg.
— VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications –.
— U.S. commercial launch of VAZALORE planned for third quarter 2021 –.
Over the last 12 months, PLXP stock rose by 54.05%. The one-year PLx Pharma Inc. stock forecast points to a potential upside of 2.78. The average equity rating for PLXP stock is currently 2.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $121.89 million, with 9.16 million shares outstanding and 6.36 million shares in the current float. Compared to the average trading volume of 86.66K shares, PLXP stock reached a trading volume of 3513495 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on PLx Pharma Inc. [PLXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PLXP shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PLXP stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for PLx Pharma Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 12, 2019, representing the official price target for PLx Pharma Inc. stock.
The Average True Range (ATR) for PLx Pharma Inc. is set at 0.92, with the Price to Sales ratio for PLXP stock in the period of the last 12 months amounting to 2243.75.
PLXP Stock Performance Analysis:
PLx Pharma Inc. [PLXP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.19. With this latest performance, PLXP shares gained by 58.23% in over the last four-week period, additionally plugging by 109.08% over the last 6 months – not to mention a rise of 54.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PLXP stock in for the last two-week period is set at 66.24, with the RSI for the last a single of trading hit 68.60, and the three-weeks RSI is set at 65.06 for PLx Pharma Inc. [PLXP]. The present Moving Average for the last 50 days of trading for this stock 6.45, while it was recorded at 7.66 for the last single week of trading, and 4.33 for the last 200 days.
Insight into PLx Pharma Inc. Fundamentals:
PLx Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
PLXP Stock EPS
With the latest financial reports released by the company, PLx Pharma Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 47.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PLXP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for PLx Pharma Inc. go to 40.00%.
PLx Pharma Inc. [PLXP] Insider Position Details
There are presently around $19 million, or 36.40% of PLXP stock, in the hands of institutional investors. The top three institutional holders of PLXP stocks are: PARK WEST ASSET MANAGEMENT LLC with ownership of 1,473,218, which is approximately 0% of the company’s market cap and around 3.40% of the total institutional ownership; VANGUARD GROUP INC, holding 294,595 shares of the stock with an approximate value of $2.58 million in PLXP stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $1.22 million in PLXP stock with ownership of nearly 79.039% of the company’s market capitalization.
5 institutional holders increased their position in PLx Pharma Inc. [NASDAQ:PLXP] by around 129,041 shares. Additionally, 6 investors decreased positions by around 63,343 shares, while 8 investors held positions by with 1,928,342 shares. The mentioned changes placed institutional holdings at 2,120,726 shares, according to the latest SEC report filing. PLXP stock had 3 new institutional investments in for a total of 67,437 shares, while 3 institutional investors sold positions of 34,562 shares during the same period.